The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
Official Title: A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Study ID: NCT01883362
Brief Summary: To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem cell transplant,
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California San Diego Moores Cancer Center, La Jolla, California, United States
University of California at Los Angeles Oncology, Los Angeles, California, United States
SCRI- Colorado Blood Cancer Institute, Denver, Colorado, United States
H Lee Moffitt Cancer Center and Research Institute Oncology, Tampa, Florida, United States
Northside Hospital, Atlanta, Georgia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Karmanos Cancer Institute Karmanos - Wayne State, Detroit, Michigan, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Washington University School Of Medicine-Siteman Cancer Ctr Washington U School of Med, Saint Louis, Missouri, United States
Hackensack University Medical Center Hackensack Univ Med Ctr (32), Hackensack, New Jersey, United States
University of North Carolina at Chapel Hill University of North Carolina 6, Chapel Hill, North Carolina, United States
University Hospitals Case Medical Center, Cleveland, Ohio, United States
Oregon Health Sciences University, Portland, Oregon, United States
Tennessee Oncology Sarah Cannon Research Inst., Nashville, Tennessee, United States
Vanderbilt Univeristy Oncology, Nashville, Tennessee, United States
Baylor Health Care System/Sammons Cancer Center Oncology, Dallas, Texas, United States
Texas Transplant Physicians Group Oncology 2, San Antonio, Texas, United States
Fred Hutchinson Cancer Research Center Oncology, Seattle, Washington, United States
Novartis Investigative Site, Toronto, Ontario, Canada
Name: Brian Elliott, MD
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR